Phase 1 Study of ELX-02 in Healthy Adult Subjects

Clinical trial NCT03309605 · COMPLETED

Trial details

NCT number: NCT03309605
Sponsor: Eloxx Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Genetic Disease Nonsense Mutation

Start date: 2017-10-11
Primary completion: 2019-06-17
Enrollment: 62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.